Literature DB >> 16414269

Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity.

Jamie F S Mann1, Hannah E Scales, Eisin Shakir, James Alexander, Katharine C Carter, Alexander B Mullen, Valerie A Ferro.   

Abstract

Protein antigens administered via the oral route are exposed to a hostile environment in the gastrointestinal tract, consisting of digestive enzymes and a range of pH (1-7.5). Using a delivery system can afford protection to entrapped components against degradation and permit delivery of antigen to the cells responsible for generating local and systemic immune responses. In this comparative study, mice were immunised orally with tetanus toxoid (40 or 200 microg dose/mouse, four doses in total) entrapped in non-ionic surfactant vesicles formulated with bile salts (bilosomes). The higher entrapped dose (BV-TT, 200 microg) induced IgG1 by study week 3 to similar levels to those observed with subcutaneous un-entrapped TT at the lower (<50 microg) dose. However, both bilosome formulations (BV-TT, low, and high doses), though not un-entrapped TT, caused a rise in the numbers of IgA positive plasma cells observed in the small intestine, primarily in the first 15 cm of the small intestine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16414269     DOI: 10.1016/j.ymeth.2005.11.002

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  11 in total

1.  Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes.

Authors:  Sunee Channarong; Wanpen Chaicumpa; Nuttanan Sinchaipanid; Ampol Mitrevej
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

Review 2.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

Review 3.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

4.  Tetanus toxoid-loaded layer-by-layer nanoassemblies for efficient systemic, mucosal, and cellular immunostimulatory response following oral administration.

Authors:  Harshad Harde; Ashish Kumar Agrawal; Sanyog Jain
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

Review 5.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

6.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

Review 7.  Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.

Authors:  Pavimol Angsantikul; Ronnie H Fang; Liangfang Zhang
Journal:  Bioconjug Chem       Date:  2017-12-27       Impact factor: 4.774

Review 8.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

Review 9.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

10.  Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice.

Authors:  Balraj Premanand; Mookkan Prabakaran; Tanja K Kiener; Jimmy Kwang
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.